We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them
News

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them
News

Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Morphotek Receives U.S. Patent Regarding Methods for Generating Genetically Altered Antibodies with Enhanced Affinity and Antibodies Produced by Them"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Morphotek, Inc. has announced the issuance of United States Patent No. 7,235,643 B2 (the “643” patent). The patent relates to certain methods of enhancing the affinity of monoclonal antibodies (mAbs). It illustrates the company’s MORPHODOMA® technology, a whole genome evolution platform that can enhance cells producing mAbs to yield daughter cells producing antibodies with enhanced pharmacologic activity.

MORPHODOMA® technology enhances evolution within cells through the reversible regulation of the mismatch repair (MMR) pathway, a highly conserved process employed by all living organisms to repair mutations that naturally occur during DNA replication.

Dr. Philip Sass, Executive Vice President and Chief Operating Officer of Morphotek, commented, “This patent further strengthens Morphotek’s competitive advantage in the field of antibody discovery and development. The use of our MORPHODOMA® technology enables our researchers to generate high affinity antibodies from lead target-specific antibodies with low affinity. This platform allows for the rapid and efficient optimization of antibodies for clinical development and proof-of-concept evaluation for use in treating disease.”

Advertisement